Related Experiment Videos
[A benign form of chronic lympholeukemia]
Terapevticheskii Arkhiv
|January 1, 1997
Summary
Benign chronic lymphocytic leukemia (CLL) is a slow-progressing form of the disease. This study found benign CLL patients have a median survival of 22 years, with no tumor progression causing death.
Area of Science:
- Hematology
- Oncology
Background:
- The Vorob'ev and Brilliant classification (1983) defines benign chronic lymphocytic leukemia (CLL) as a distinct entity.
- Benign CLL is characterized by low lymphocytosis, minimal lymphadenopathy, and slow progression, often not requiring therapy.
Observation:
- A study analyzed 34 benign CLL cases (17 males, 17 females, mean age 58).
- Patients had lymphocyte counts <30,000 and stable lymphoid tissue for ≥3 years, with follow-up averaging 11 years.
- Key features included absence of "B" symptoms, minimal organ enlargement, stable lymphocytosis, low prolymphocytes (0.95% +/- 0.2), and nodular bone marrow patterns.
Findings:
- Immunophenotype typical for CLL (CD19+, CD20+, CD23+, CD5+) was observed in 91% of cases.
- No cases showed paraprotein secretion or positivity for the CD38 activation marker.
- One case of trisomy 12 was detected via FISH; 8 patients died, but not from CLL progression, with a median survival of 22 years.
Implications:
- Benign CLL represents an indolent subset of CLL with an excellent prognosis.
- The findings support the distinct classification and management approach for benign CLL.
- Further research can refine diagnostic criteria and long-term monitoring strategies for this specific CLL subtype.